TrialEuropean heart journal. Quality of care & clinical outcomes2022

Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.

Mark H Rozenbaum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.